Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesHIV protease inhibitors: recent clinical trials and recommendations on use
Expert Opinion in Pharmacotherapy, 06/19/09
Fernandez-Montero JV et al. - Due to their characteristics, PIs are, and will remain, a cornerstone component in most lines of antiretroviral therapy. The antiviral activity, tolerability and convenience of PIs have improved significantly in recent years. Differences between compounds within this class may favour their use in specific situations, such as the friendly metabolic profile of atazanavir in patients with cardiovascular disease or the high genetic barrier of darunavir or tipranavir in heavily pretreated individuals with HIV.
Related Articles
Prevalence and Correlates of Elevated Body Mass Index among HIV-Positive and HIV-Negative Women in the Womens Interagency HIV Study
AIDS Patient Care and STDs, 11/19/09
Relevance Score: 95%
Effectiveness of Increasing Emergency Department Patients' Self-perceived Risk for Being Human Immunodeficiency Virus (HIV) Infected Through Audio Computer Self-interview–based Feedback About Reported HIV Risk Behaviors
Academic Emergency Medicine, 11/11/09
Relevance Score: 95%
HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09
Relevance Score: 95%
War and Peace between Microbes: HIV-1 Interactions with Coinfecting Viruses
Cell Host & Microbe, 11/23/09
Relevance Score: 94%
Mediators of HIV-related stigma and risk behavior in HIV infected young women
AIDS Care, 11/12/09
Relevance Score: 94%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/15/09
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Annual Progression of Coronary Calcification in Trials of Preventive Therapies
Archives of Internal Medicine, 12/15/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability
Journal of Pharmacy and Pharmacology, 12/15/09
Novel TNF antagonists for the treatment of rheumatoid arthritis
Expert Opinion on Investigational Drugs, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor